Diederik P. D. Suurd

Diederik P. D. Suurd

Auto-generated profile, based on publicly available information

Diederik P. D. Suurd

Department of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in The American Journal of Surgery
Verified
Journal Article
Open access
DSDiederik P.D. Suurd
Diederik P.D. Suurd
WVWessel M.C.M. Vorselaars
Wessel M.C.M. Vorselaars
DBDirk-Jan Van Beek
Dirk-Jan Van Beek
WSWilko Spiering
Wilko Spiering
IRInne H.M. Borel Rinkes
Inne H.M. Borel Rinkes
MVMenno R. Vriens
Menno R. Vriens
Decrease in blood pressure (BP) is the major goal of adrenalectomy for primary aldosteronism. Nevertheless, the optimal timing to assess these outcomes and the needed duration of follow-up are uncertain. We systematically reviewed the literature regarding trends in BP-related outcomes during follow-up after adrenalectomy. A systematic literature search of medical literature from PubMed, Embase and the Cochrane Library regarding BP-related outcomes (i.e. cure of hypertension rates, BP and antihypertensives) was performed. The Quality In Prognosis Studies risk of bias tool was used. Of the 2057 identified records, 13 articles met the inclusion criteria. Overall study quality was low. In multiple studies, the biggest decrease in BP was shown within the first month(s) after adrenalectomy and afterwards BP often remained stable during long-term follow-up. Based on the available studies one might suggest that long follow-up is unnecessary, since outcomes seem to stabilize within the first months.

2 April 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ASAtia Samim
Atia Samim
DSDiederik P. D. Suurd
Diederik P. D. Suurd
RRRob van Rooij
Rob van Rooij
MNMax M. Van Noesel
Max M. Van Noesel
MLMarnix G.E.H. Lam Lam
Marnix G.E.H. Lam Lam
BKBart De Keizer
Bart De Keizer
Purpose: Meta-[1⁸F]fluorobenzylguanidine ([1⁸F]mFBG) PET-CT is a novel imaging modality for norepinephrine transporter-expressing tumours, such as neuroblastoma and phaeochromocytoma, enabling quantitative assessment and improved diagnostic accuracy compared to meta-[123I]iodobenzylguanidine ([123I]mIBG) scintigraphy. This study aims to: 1) Identify the optimal standardised uptake value (SUV) normalisation method: body weight (BW) or lean body mass (LBM); 2) Determine the most stable reference tissue with SUV uptake below pathological levels. Methods: We analysed 63 [1⁸F]mFBG PET-CTs from 35 patients (20 paediatric neuroblastoma, 15 adult phaeochromocytoma). SUVmean was measured in the liver, blood pool, bone marrow, and muscle, normalised using BW (SUVBW), LBM via James (SUVLBMJames), and LBM via Janmahasatian (SUVLBMJanma). Variability of SUVs and their correlation with weight were assessed. Results: LBM-based normalisation reduced SUV variability compared to BW-based normalisation. Bone marrow demonstrated the lowest variability and least weight dependency (r2 0.45 for SUVBW versus 0.31 for SUVLBMJanma). The liver had the highest SUVs, increasing the risk of false negatives if used as reference tissue, while the blood pool had the lowest SUVs, raising the risk of false positives. Muscle showed relatively stable SUVs with increasing weight but higher variability than bone marrow. Conclusion: LBM-based SUV normalisation reduces weight dependency for [1⁸F]mFBG PET-CT. Bone marrow is the most reliable reference tissue due to its low variability and balanced SUVs, while muscle may serve as an alternative if diffuse bone marrow uptake is present. These findings support standardising LBM-adjusted SUV methods and using bone marrow as the primary reference tissue to enhance diagnostic accuracy. Clinical trial registration: EudraCT Number: 2019–003713-33; EU Clinical Trials Number: 2024–513622-35–00.

3 June 2025 in Surgery
Verified
Journal Article
Open access
DSDiederik P.D. Suurd
Diederik P.D. Suurd
MBMedard F.M. Van Den Broek
Medard F.M. Van Den Broek
CVCharlotte L. Viëtor
Charlotte L. Viëtor
TGTessa M. Van Ginhoven
Tessa M. Van Ginhoven
RFRichard A. Feelders
Richard A. Feelders
MVMenno R. Vriens
Menno R. Vriens
Adrenalectomy is considered the standard of care for multiple endocrine neoplasia type 2-related pheochromocytomas. Recently, partial adrenalectomy has been suggested as an alternative to prevent adrenal insufficiency in hereditary pheochromocytoma. Nevertheless, this comes with the risk of ipsilateral recurrence. Therefore, we aimed to determine the incidence of ipsilateral recurrence after partial adrenalectomy and assess the proportion of prevented adrenal insufficiency due to partial adrenalectomy in cases of bilateral disease. A retrospective, multicenter cohort study was conducted between 1977 and 2022 via a standardized medical record review. The primary outcome was the incidence of ipsilateral recurrence after partial adrenalectomy compared with total adrenalectomy. The secondary outcomes included disease-free survival and incidence of adrenal insufficiency and crisis after bilateral surgery. In 50 patients with multiple endocrine neoplasia type 2, a total of 88 adrenalectomies were performed, including 23 partial adrenalectomies and 65 total adrenalectomies. After a median follow-up after last surgery of 8.3 years, 7 (30.4%) of the partial adrenalectomies and 2 (3.1%) of total adrenalectomies had recurrent disease (P < .001, χ2 test). The median time to recurrence was 4 and 21 years after partial adrenalectomy and total adrenalectomy, respectively. After bilateral surgery with at least partial adrenalectomy on one side, 50.0% of patients did not require corticosteroids. These data show that there is a considerable risk of ipsilateral recurrent disease in the short term after partial adrenalectomy for multiple endocrine neoplasia type 2-related pheochromocytoma with a 50% chance of adrenal insufficiency in cases of bilateral surgery. Therefore, we doubt whether partial adrenalectomy should be preferred for multiple endocrine neoplasia type 2-associated pheochromocytoma. We propose total adrenalectomy as the standard technique and partial adrenalectomy only for selected cases.